Oxford University and Astrazeneca announced interim results from the phase 3 trial of their coronavirus vaccine. The results are promising with efficacy scores ranging from 70% to possibly 90%, depending on the dose of the first of the two inoculations. This vaccine also remains viable when stored at refrigerator temperatures – a logistical advantage compared to the Pfizer and Moderna vaccines. Claudia consults Charlie Wheeler, head of vaccines at the Wellcome Trust, about how this vaccine may advance the ambition of protecting the world from Covid-19. The pandemic has disrupted routine health services in many countries. Maternity services for pregnant women and women in labour have not escaped restrictions. In the UK this has included banning partners from clinics and wards, often for most of labour. Dr Samara Linton reports. High levels of lead exposure in childhood result in smaller, less robust-looking brains in middle age. This is the conclusion of a long-running study of hundreds of people who grew up in the town of Dunedin in New Zealand. They have been followed since their childhoods in the early 1970s, during the era of leaded petrol. At the age of 45, more than 550 of them have had MRI brain scans. This part of the research has been led by Aaron Reuben and Maxwell Elliot at Duke University in the United States. Although leaded petrol is banned in all but one country today, hundreds of millions of children are still exposed to environmental lead levels well above what’s regarded as safe. Epidemiologist Matthew Fox of Boston University also joins Claudia to talk about the disappointing covid antiviral drug remdesivir, coronavirus rapid tests and a flu vaccine grown in plants. Presenter: Claudia Hammond Producer: Producer: Andrew Luck-Baker (Picture: Laboratory technicians in Italy handle capped vials as part of filling and packaging tests for the large-scale production and supply of the University of Oxford’s Covid-19 vaccine. Photo credit: Vincenzo Pinto/AFP/Getty Images.)